Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4939145 | 0.80 | DGAT1 (0.40) | DGAT1 | |
| SCHEMBL9116850 | 0.80 | DGAT1 (0.40) | DGAT1 | |
| SCHEMBL28195825 | 0.80 | DGAT1 (0.40) | DGAT1 | |
| SCHEMBL28772147 | 0.80 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL4187645 | 0.78 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL25436173 | 0.77 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL2330290 | 0.77 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL30185755 | 0.77 | DGAT1 (0.38) | DGAT1 | |
| SCHEMBL10803405 | 0.76 | DGAT1 (0.34) | DGAT1 | |
| SCHEMBL28815007 | 0.76 | DGAT1 (0.36) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1989186-B1 | HYDANTOIN BASED KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-11-17 | — | — | EP | disclosed |
| US-7612212-B2 | 2-[(S)-2-((S)-2,5-dioxo-4-phenyl-imidazolidin-1-yl)-4-methyl-pentanoylamino]-thiazole-4-carboxylic acid methyl ester; mitogen activated protein/extracellular signal regulated kinase kinase inhibitor; anticarcinogenic agent, cognition activator, nervous and autoimmune system disorders | HOFFMANN-LA ROCHE INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20080207563-A1 | METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELLS | NIU HUIFENG | 2008-08-28 | — | — | US | disclosed |
| US-20070197617-A1 | Substituted hydantoins | CHEN SHAOQING | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197617-A1 | Substituted hydantoins | HNMT, HRH3, BRAF | DGAT1 3584/4885AAK1 1787/4885 |
| US-20080207563-A1 | METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELLS | MKI67, BRAF, MYC | DGAT1 1723/4885AAK1 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.